General Atlantic has led a $69 million Series D round of funding for Adagene, a Chinese drug developer with one cancer treatment currently in phase one clinical trials in China and the US.
The company has now raised more than $150 million in the past five years from the likes of F-Prime and Eight Roads – both investment arms of Fidelity International – as well as GP Capital, Sequoia...
Chinese gene therapy specialist Exegenesis Bio has received $20 million in Series B funding led by Legend Capital. It will be used to support clinical development of the company’s drug portfolio.
Alibaba Group has led a $300 million round for Chinese electric vehicle (EV) manufacturer Xpeng Motors. It comes barely two weeks after the company closed an extended Series C round of $500 million.
EDBI, the investment arm of Singapore’s Economic Development Board, has invested in Vesta, a US-based fraud and payment technology start-up with ambitions to expand into Asia.
Hana Financial has invested KRW100 billion ($85 million) in a portfolio of Korean waste to energy (WTE) projects controlled by Global Infrastructure Partners (GIP).